Pharming Group (PHAR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $37.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Pharming Group’s potential for growth and market expansion. The recent publication in Cell underscores a significant advancement in diagnosing primary immune disorders, specifically APDS, by addressing the challenge of genetic variants of uncertain significance. This research paves the way for more accurate diagnoses, potentially increasing the number of patients eligible for treatment with leniolisib (Joenja).
Furthermore, the functional screening approach developed by Columbia researchers has revealed that APDS may be more prevalent than previously estimated, affecting a larger population. This could lead to increased clinical awareness and reclassification of genetic test results, allowing more patients to access targeted treatments. As genetic testing labs update their reports, the potential for broader drug uptake and market penetration for Joenja aligns with Pharming’s strategic plans for expansion, supporting the Buy rating.